Key result
Novel antithrombotic therapies aim to inhibit pathological thrombosis while enabling normal haemostasis to minimize the risk of bleeding.
This review discusses novel antithrombotic strategies aimed at inhibiting pathological thrombosis while preserving normal haemostasis to minimize bleeding risk.
May support safer antithrombotic strategies separating thrombosis from haemostasis; leaves open clinical translation pending prospective trials.
Thrombi are composed of activated platelets and fibrin, the latter being the final product of the blood coagulation system. Therefore, antithrombotic therapies may either interfere with adhesion, aggregation, secretion or signalling of platelets or with fibrin formation. Established drugs potently inhibit clot formation, but also increase the risk of bleeding. In this review article, we discuss novel strategies for the inhibition of pathological thrombosis while enabling normal haemostasis, thus minimizing the risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Bäuml et al. (2018) conducted a review in Pathological thrombosis. Novel antithrombotic therapies was evaluated. Novel antithrombotic therapies aim to inhibit pathological thrombosis while enabling normal haemostasis to minimize the risk of bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: